Product Description
Ixazomib is used in combination with lenalidomide (Revlimid) and dexamethasone to treat multiple myeloma (cancer of the plasma cells in the bone marrow) that has worsened after treatment with other chemotherapy medications. Ixazomib is in a class of medications called proteasome inhibitors. It works by helping to kill cancer cells. (Sourced from: https://medlineplus.gov/druginfo/meds/a616008.html)
Mechanisms of Action: Proteasome Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States
Approved Indications: Multiple Myeloma
Known Adverse Events: Back Pain | Pain Unspecified | Thrombocytopenia | Contraception | Pregnancy Outcomes | Constipation | Diarrhea | Edema
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Croatia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Lithuania, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Romania, Russia, Serbia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 47
Highest Development Phases
Phase 3: Amyloidosis|Multiple Myeloma|Stem Cell Transplant
Phase 2: Acute Lymphoid Leukemia|Allogeneic Stem Cell Transplant|Graft vs Host Disease|Kidney Failure, Chronic|Lymphoma|Lymphoma, Non-Hodgkin|Mantle-Cell Lymphoma|Oncology Unspecified|Precursor Cell Lymphoblastic Leukemia-Lymphoma|T-Cell Peripheral Lymphoma
Phase 1: Acute Myeloid Leukemia|Gastrointestinal Cancer|Kidney Cancer|Kidney Diseases|Liver Cancer|Mouth Cancer|Multiple Sclerosis, Chronic Progressive|Multiple Sclerosis, Relapsing-Remitting|Non-Small-Cell Lung Cancer|Pregnancy Outcomes|Small Cell Lung Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NMSG#23/15 | P2 |
Active, not recruiting |
Multiple Myeloma |
2027-12-31 |
|
| HCC 21-200 | P2 |
Recruiting |
Multiple Myeloma |
2026-10-01 |
|
| FIXATION | P2 |
Recruiting |
Mantle-Cell Lymphoma |
2026-05-31 |
|
| NMSG#23/15 IRd | P2 |
Active, not recruiting |
Multiple Myeloma |
2026-05-24 |